Turning Point Benefit Group, Inc. Vaxcyte, Inc. Transaction History
Turning Point Benefit Group, Inc.
- $191 Billion
- Q4 2025
A detailed history of Turning Point Benefit Group, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Turning Point Benefit Group, Inc. holds 20 shares of PCVX stock, worth $966. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$966% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
326Shares Held
132MCall Options Held
408KPut Options Held
116K-
Janus Henderson Group PLC London, X013.1MShares$633 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$589 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$578 Million7.4% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$480 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.32MShares$402 Million0.18% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.87B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...